Constitutive activation of Hedgehog (Hh) signaling has been implicated in many cancers including hepatocellular carcinoma (HCC). Among them, the terminal glioma-associated oncogene homolog 1 (Gli1) regulates the expression of critical genes in the Hh pathway. The current study aims to evaluate the anti-HCC effect of the Gli1 inhibitor, GANT61. In vitro analysis including cell counting kit-8 (CCK-8) assay, flow cytometry, and migration and invasion assay were adopted to evaluate the effect of GANT61 on HCC cell lines. In vivo, xenograft studies were also performed to verify the effect of GANT61 on HCC. By CCK-8 assay, we found that GANT61 could significantly reduce the growth of HCC cell lines Huh7 and hemophagocytic lymphohistiocytosis (HLE), and their IC50 concentrations were 4.481 and 6.734 μM, respectively. Flow cytometry shows that GANT61 induced cell cycle arrest in the G2/M phase and accelerated apoptosis of both HLE and Huh7 cells. While migration and invasion assay shows that GANT61 weakens cells’ migration and invasion ability. Besides that, GANT61 inhibits the expression of Gli1, FoxM1, CyclinD1, and Bcl-2, upregulates the level of Bax protein, and also reverses the epithelial–mesenchymal transition program by downregulating the expression of Vimentin and N-Cadherin and upregulating the expression of epithelial E-Cadherin expression. Furthermore, GANT61 inhibits the growth of subcutaneous xenografts of Huh7 cells in nude mice. Overall, this study suggests that Gli1 is a potential target for therapy and GANT61 shows promising therapeutic potential for future treatment in HCC.
SiegelRLMillerKDJemalA.Cancer statistics, 2017. CA Cancer J Clin2017; 67: 7–30.
2.
JiangJHuiCC.Hedgehog signaling in development and cancer. Dev Cell2008; 15: 801–812.
3.
HeisenbergCPSolnica-KrezelL.Back and forth between cell fate specification and movement during vertebrate gastrulation. Curr Opin Genet Dev2008; 18: 311–316.
4.
D’AmicoDCanettieriG.Translating hedgehog in cancer: controlling protein synthesis. Trends Mol Med2016; 22: 851–862.
5.
PietanzaMCLitvakAMVargheseAM, et al. A phase I trial of the hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer. Lung Cancer2016; 99: 23–30.
6.
ShalapourSLinXJBastianIN, et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature2017; 551: 340–345.
7.
KonstantinouDBertaux-SkeirikNZavrosY.Hedgehog signaling in the stomach. Curr Opin Pharmacol2016; 31: 76–82.
8.
FuJRodovaMRoySK, et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett2013; 330: 22–32.
9.
WickstromMDybergCShimokawaT, et al. Targeting the Hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Int J Cancer2013; 132: 1516–1524.
10.
JengKSJengCJJengWJ, et al. Sonic Hedgehog signaling pathway as a potential target to inhibit the progression of hepatocellular carcinoma. Oncol Lett2019; 18: 4377–4384.
11.
KreisingerovaKOndrusovaUHorakP, et al. Importance of aberrantly activated Hedgehog/Gli pathway in tumour progression. Klin Onkol2020; 33: 177–183.
12.
Grund-GroschkeSStockmaierGAbergerF.Hedgehog/GLI signaling in tumor immunity—new therapeutic opportunities and clinical implications. Cell Commun Signal2019; 17: 172.
13.
HaradaKOhashiRNaitoK, et al. Hedgehog signal inhibitor GANT61 inhibits the malignant behavior of undifferentiated hepatocellular carcinoma cells by targeting non-canonical GLI signaling. Int J Mol Sci2020; 21: 3126.
14.
OzreticPTrnskiDMusaniV, et al. Non-canonical Hedgehog signaling activation in ovarian borderline tumors and ovarian carcinomas. Int J Oncol2017; 51: 1869–1877.
15.
ZhouJZhuGHuangJ, et al. Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: a novel potential therapeutic target. Cancer Lett2016; 370: 313–323.
16.
PoASilvanoMMieleE, et al. Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma. Oncogene2017; 36: 4641–4652.
17.
ZhangRWuJFerrandonS, et al. Targeting GLI by GANT61 involves mechanisms dependent on inhibition of both transcription and DNA licensing. Oncotarget2016; 7: 80190–80207.
18.
LiJCaiJZhaoS, et al. GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment. J Exp Clin Cancer Res2016; 35: 184.
19.
BellaLZonaSNestaldeMoraesG, et al. FOXM1: a key oncofoetal transcription factor in health and disease. Semin Cancer Biol2014; 29: 32–39.
20.
LiROkadaHYamashitaT, et al. FOXM1 is a novel molecular target of AFP-positive hepatocellular carcinoma abrogated by proteasome inhibition. Int J Mol Sci2022; 23: 8305.
21.
HuGYanZZhangC, et al. FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression. J Exp Clin Cancer Res2019; 38: 188.
22.
WangYWangHYanZ, et al. The critical role of dysregulated Hh-FOXM1-TPX2 signaling in human hepatocellular carcinoma cell proliferation. Cell Commun Signal2020; 18: 116.
23.
PalleKManiCTripathiK, et al. Aberrant GLI1 activation in DNA damage response, carcinogenesis and chemoresistance. Cancers2015; 7: 2330–2351.
24.
KasaiK.GLI1, a master regulator of the hallmark of pancreatic cancer. Pathol Int2016; 66: 653–660.
25.
InfantePAlfonsiRBottaB, et al. Targeting GLI factors to inhibit the Hedgehog pathway. Trends Pharmacol Sci2015; 36: 547–558.
26.
ElitLMHirteH.Management of advanced or recurrent cervical cancer: chemotherapy and beyond. Expert Rev Anticancer Ther2014; 14: 319–332.
27.
ReiterFPBen KhaledNYeL, et al. Advances in pharmacotherapy of hepatocellular carcinoma: a state-of-the-art review. Dig Dis2022; 40: 565–580.
28.
ZhangXTianYYangY, et al. Development of anticancer agents targeting the Hedgehog signaling. Cell Mol Life Sci2017; 74: 2773–2782.
29.
TangJYAllyMSChananaAM, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol2016; 17: 1720–1731.
30.
DrenoBKunstfeldRHauschildA, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol2017; 18: 404–412.
31.
JimenoAWeissGJMillerWHJr, et al. Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res2013; 19: 2766–2774.
32.
DessiniotiCPlakaMStratigosAJ.Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial. Future Oncol2014; 10: 927–936.
33.
BrinkhuizenTReindersMGvan GeelM, et al. Acquired resistance to the hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. J Am Acad Dermatol2014; 71: 1005–1008.
34.
AgyemanAJhaBKMazumdarT, et al. Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding. Oncotarget2014; 5: 4492–4503.
35.
ArnholdVBoosJLanvers-KaminskyC.Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors. Cancer Chemother Pharmacol2016; 77: 495–505.
36.
BenvenutoMMasuelliLDe SmaeleE, et al. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. Oncotarget2016; 7: 9250–9270.
37.
WangDHuGDuY, et al. Aberrant activation of hedgehog signaling promotes cell proliferation via the transcriptional activation of forkhead Box M1 in colorectal cancer cells. J Exp Clin Cancer Res2017; 36: 23.
38.
ZhangCWangYFengY, et al. Gli1 promotes colorectal cancer metastasis in a Foxm1-dependent manner by activating EMT and PI3K-AKT signaling. Oncotarget2016; 7: 86134–86147.
39.
KenneyAMRowitchDH.Sonic hedgehog promotes G(1) cyclin expression and sustained cell cycle progression in mammalian neuronal precursors. Mol Cell Biol2000; 20: 9055–9067.
40.
ZhangMJiangMBiY, et al. Autophagy and apoptosis act as partners to induce germ cell death after heat stress in mice. PloS One2012; 7: e41412.
41.
JungYYLeeYKKooJS.The potential of Beclin 1 as a therapeutic target for the treatment of breast cancer. Expert Opin Ther Targets2016; 20: 167–178.
42.
KatohYKatohM.Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review). Int J Mol Med2008; 22: 271–275.
43.
YuCPYuSShiL, et al. FoxM1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma by targeting Snai1. Mol Med Rep2017; 16: 5181–5188.
